Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358549 · ClinicalTrials.gov registry record · Phase 2
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
A Phase 2 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT04358549: Completed Phase 2 study, sponsored by Fujifilm Pharmaceuticals U.S.A..
NCT04358549 is a Phase 2 study that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04358549, a Phase 2 study, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
Primary Outcome
To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal sampling
Interventions
- OTHER Standard of Care
- DRUG Favipiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-04-17 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
What the finished NCT04358549 record still lists
NCT04358549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04358549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04358549 about?
NCT04358549 is a clinical study titled "Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19". To determine the effect of favipiravir + SOC v. SOC on COVID-19 viral clearance.
What is the current status of trial NCT04358549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-04-17. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04358549?
The interventions under investigation include: Standard of Care (OTHER), Favipiravir (DRUG).
Who is sponsoring clinical trial NCT04358549?
This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04358549's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI